Bavarian Nordic A/S is a Danish biotechnology company focused on the research, development, manufacturing, and supply of vaccines for infectious diseases. The company is known for its proprietary MVA-BN (Modified Vaccinia Ankara) viral vector platform and for licensed smallpox/monkeypox vaccines (marketed as Jynneos/Imvanex/Imvamune). Its activities span R&D through large-scale production and quality-controlled fill–finish operations, supporting public health preparedness and routine immunization markets.
The portfolio includes travel and endemic disease vaccines such as rabies (Rabipur/RabAvert), tick-borne encephalitis (Encepur), cholera (Vaxchora), and typhoid (Vivotif), alongside a pipeline of vaccine candidates targeting emerging and respiratory pathogens. Bavarian Nordic serves governments, health agencies, and commercial channels worldwide, with manufacturing centered in Denmark and a global distribution footprint. The company is listed on Nasdaq Copenhagen under the ticker BAVA.
None yet. When a new project in the record names Bavarian Nordic as owner, partner or investor, it shows here.
The EU funds next-gen flu vaccines to enhance protection, speed up development, and improve pandemic readiness through pre-commercial procurement.
